Capital News

Adult-Onset Still Disease Pipeline and Clinical Trials 2023 | Key Companies – AB2 Bio Ltd., Cerecor, Roche, Swedish Orphan Biovitrum, and others

 Breaking News
  • No posts were found

Adult-Onset Still Disease Pipeline and Clinical Trials 2023 | Key Companies – AB2 Bio Ltd., Cerecor, Roche, Swedish Orphan Biovitrum, and others

May 23
21:15 2023
Adult-Onset Still Disease Pipeline and Clinical Trials 2023 | Key Companies - AB2 Bio Ltd., Cerecor, Roche, Swedish Orphan Biovitrum, and others

DelveInsight’s, “Adult-Onset Still Disease Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Adult-Onset Still Disease pipeline landscape. It covers the Adult-Onset Still Disease pipeline drug profiles, including Adult-Onset Still Disease clinical trials and nonclinical stage products. It also covers the Adult-Onset Still Disease therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Recent Developmental Activities in the Adult-Onset Still Disease Treatment Landscape

 

  • Ilaris (canakinumab) injectable has been authorized by the US Food and Drug Administration (FDA) for the treatment of adult patients with active Still disease, a rare autoimmune condition with no known cause.

 

Request a sample and discover the recent breakthroughs happening in the Adult-Onset Still Disease Pipeline landscape @ Adult-Onset Still Disease Pipeline Outlook

 

Adult-Onset Still Disease Overview

Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder that affects the entire body (systemic disease). The cause of the disorder is unknown (idiopathic). It has similar symptoms to systemic-onset juvenile idiopathic arthritis – fever, rash, and joint pain. The specific symptoms and frequency of episodes vary from one person to another and the progression of the disorder is difficult to predict. In some individuals, the disorder appears suddenly, disappears almost as quickly and may not return. In other people, adult-onset Still’s disease is a chronic, potentially disabling, condition.

 

Key Takeaways from the Adult-Onset Still Disease Pipeline Report

 

  • DelveInsight’s Adult-Onset Still Disease Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Adult-Onset Still Disease treatment.

 

  • The leading Adult-Onset Still Disease Companies include AB2 Bio Ltd., Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum and others

 

  • Promising Adult-Onset Still Disease Pipeline Therapies include Canakinumab, Anakinra, Tadekinig alfa, CERC-007, Tocilizumab (TCZ), Anakinra, and others

 

  • The Adult-Onset Still Disease companies and academics are working to assess challenges and seek opportunities that could influence Adult-Onset Still Disease R&D. The Adult-Onset Still Disease therapies under development are focused on novel approaches to treat/improve Adult-Onset Still Disease.

 

For further information, refer to the detailed Adult-Onset Still Disease Drugs Launch, Adult-Onset Still Disease Developmental Activities, and Adult-Onset Still Disease News, click here for Adult-Onset Still Disease Ongoing Clinical Trial Analysis

 

 Adult-Onset Still Disease Emerging Drugs Profile

 

Tadekinig alfa: AB2 Bio Ltd.

Tadekinig alfa is the drug name for recombinant human interleukin-18 binding protein (IL-18BP). It is currently under phase 2 of clinical trials for the indication Adult-onset Still’s disease.

 

CERC-007: Cerecor

CERC-007 is a fully human anti-IL-18 monoclonal antibody with the potential to address multiple auto-inflammatory diseases, including Adult-onset Still’s disease (AOSD) and multiple myeloma (MM). IL-18 is a pro-inflammatory cytokine; patients with AOSD and MM shows elevated levels of IL-18. Cerecor seeks to initiate a phase 1b/2a proof-of-concept study of CERC-007 in AOSD and MM patients in 2020.

 

Tocilizumab (TCZ) – Roche

TCZ is a humanized anti-IL-6R antibody that binds to both soluble and membranebound IL-6 receptors (sIL-6R and mIL-6R), inhibiting sIL-6R and mIL-6R-mediated signaling. TCZ is available for intravenous (IV) infusion and subcutaneous (SC) injections. It is registered for the indication Adult-onset Still’s disease.

 

Anakinra – Swedish Orphan Biovitrum

Anakinra is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra). The drug is produced by recombinant DNA technology using an E. coli bacterial expression system. Anakinra is useful for treating rheumatoid arthritis (RA) and some other inflammatory conditions. It is registered for the indication Adult-onset Still’s disease.

 

Adult-Onset Still Disease Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Adult-Onset Still Disease. The companies which have their Adult-Onset Still Disease drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, AB2 Bio Ltd. and others.

 

Find out more about the Adult-Onset Still Disease Pipeline Segmentation, Therapeutics Assessment, and Adult-Onset Still Disease Emerging Drugs @ Adult-Onset Still Disease Treatment Landscape

 

Scope of the Adult-Onset Still Disease Pipeline Report

 

  • Coverage- Global

 

  • Adult-Onset Still Disease Companies- AB2 Bio Ltd., Cerecor, Roche, Swedish Orphan Biovitrum, Novartis, Swedish Orphan Biovitrum and others

 

  • Adult-Onset Still Disease Pipeline Therapies- Canakinumab, Anakinra, Tadekinig alfa, CERC-007, Tocilizumab (TCZ), Anakinra, and others

 

  • Adult-Onset Still Disease Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Adult-Onset Still Disease Pipeline Companies and Therapies, click here @ Adult-Onset Still Disease Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Adult-Onset Still Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Adult-Onset Still Disease – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Adult-Onset Still Disease Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Drug profiles in the detailed report…..
  11. Mid Stage Products (Phase II)
  12. Tadekinig: AB2 Bio ltd.
  13. Drug profiles in the detailed report…..
  14. Pre-clinical and Discovery Stage Products
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Adult-Onset Still Disease Key Companies
  18. Adult-Onset Still Disease Key Products
  19. Adult-Onset Still Disease- Unmet Needs
  20. Adult-Onset Still Disease- Market Drivers and Barriers
  21. Adult-Onset Still Disease- Future Perspectives and Conclusion
  22. Adult-Onset Still Disease Analyst Views
  23. Adult-Onset Still Disease Key Companies
  24. Appendix

 

Got Queries? Find out the related information on Adult-Onset Still Disease Mergers and acquisitions, Adult-Onset Still Disease Licensing Activities @ Adult-Onset Still Disease Recent Trends, and Future Perspectives

 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services